One in Five Britons Suffer from Asthma
As cold air and low temperatures set in, independent analyst firm Datamonitor Healthcare has revealed that around one in five Britons will suffer the effects of asthma this winter.
Across the five major EU markets* the UK has the highest prevalence of diagnosed asthmatics with 18% or 11.1 million of the population living with the condition. The numbers and hence the proportion of population living with asthma is lower in other countries in the five major EU markets where prevalence proportions only range from 6% to 11%.
Sabada Dube, lead epidemiologist at Datamonitor Healthcare commented: “Although the actual prevalent proportion of diagnosed asthma will remain constant in the next 10 years, the actual number of people with asthma is set to increase steadily, hitting about 11.4 million by 2021."
Asthma is a condition that affects the airways, which carry air in and out of the lungs. When someone comes into contact with an asthma trigger, such as cold air, the respiratory muscles tighten, making it difficult to breathe.
According to research by Datamonitor Healthcare, rising population numbers together with the launch of new biologic therapies and other pipeline products will see the asthma market continue its trend of solid growth. In the UK, sales for asthma are expected to reach $1.2 billion by 2021.
* The 5 major EU markets are France, Germany, Italy, Spain and the UK
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance